Treatment type

Oral Medicine

Treatments and trials using Oral Medicine. Filter by country, access level, or patient stories.

All countries United States Canada United Kingdom Japan China Australia Switzerland European Union Newest Patient Stories

Health Canada/FDA ApprovedUnited States Canada Switzerland European Union

Once-Weekly Oral Medicine for Kids’ BRAF Brain Tumors

Ojemda (tovorafenib) — once-weekly oral RAF inhibitor for BRAF-altered pediatric low-grade glioma

Ojemda (tovorafenib) is a weekly medicine for children’s low-grade glioma with certain BRAF gene changes, after earlier treatment.

This is for children and young people — and caregivers — facing relapsed or refractory pediatric low-grade glioma with a BRAF fusion, rearrangement, or V600…

October 9, 2026

Health Canada/FDA ApprovedUnited States Canada United Kingdom Japan Australia Switzerland European Union

New Pill for Chronic Hives Not Controlled by Antihistamines

Rhapsido (remibrutinib) for adult chronic spontaneous urticaria still active on H1 antihistamines

The FDA, Health Canada, the European Commission, and the UK MHRA have labelled an oral BTK inhibitor — 25 mg twice daily — for adults with chronic spontaneous…

Rhapsido (remibrutinib) is a twice-daily pill for adults whose chronic hives continue despite antihistamines (United States, Canada, Europe, United Kingdom).

September 7, 2026